Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE)

Silvia Della Casa, A. Stigliano, I. Chiodini, R. Giordano, A. Faggiano, L. Canu, P. Loli, M. Luconi, F. Mantero, M. Terzolo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

29 Citazioni (Scopus)

Abstract

1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials.
Lingua originaleEnglish
pagine (da-a)103-121
Numero di pagine19
RivistaJournal of Endocrinological Investigation
Volume39
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Adjuvant treatment
  • Adrenal Cortex Neoplasms
  • Adrenocortical Carcinoma
  • Adrenocortical carcinoma
  • Biopsy, Fine-Needle
  • Consensus
  • Diagnostic Imaging
  • Diagnostic Techniques, Endocrine
  • Hormones
  • Humans
  • Italy
  • Magnetic Resonance Imaging
  • Mitotane
  • Overall survival
  • Positron-Emission Tomography
  • Prognostic factors
  • Recurrence-free survival
  • Tomography, X-Ray Computed

Fingerprint

Entra nei temi di ricerca di 'Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE)'. Insieme formano una fingerprint unica.

Cita questo